AX specialist LG CNS is accelerating its push into the pharmaceutical and biotech AX market by signing a contract for a drug development-related project promoted by the Ministry of Health and Welfare and completing an automated product quality evaluation system for Chong Kun Dang.

LG CNS will participate as a contractor in the Ministry of Health and Welfare’s K-AI drug development preclinical and clinical model development project (R&D). It is a large national research project that will receive about 37.1 billion won in government support over 4 years and 3 months.

In the project, LG CNS will lead development of an AI-based clinical trial design and support platform for drug development. It will also build an integrated management framework to link various drug development AI models developed by other participating institutions using agentic AI to boost synergies.

LG CNS plans to raise drug development success rates by using a bio AI platform that combines specialized capabilities for the pharmaceutical and biotech industry, including protein structure analysis and design, with the latest AI technologies. LG CNS also automated the work of preparing Chong Kun Dang’s annual product quality review reports (APQR, Annual Product Quality Review) using agentic AI.

Using LG CNS’ enterprise agentic AI platform, AgenticWorks, it implemented a multi-agent architecture in which about 30 AI agents autonomously collaborate from data collection and analysis to verification and report drafting. The company said a few clicks can collect, analyze and verify all data from key systems such as the quality management system (QMS) and laboratory information management system (LIMS) and complete the report in one go.

Tae-hoon Kim (김태훈), vice president and head of LG CNS’ AI Cloud Business Division, said, "Our pharmaceutical and biotech AX capabilities have been recognized by the government and pharmaceutical companies, and we are delivering tangible results." He said, "By leading agentic AI technology, we will strengthen the competitiveness of Korea’s pharmaceutical and biotech industry and become a game changer that provides differentiated customer value."